Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis May 12, 2021
GBR-830 shows improvement at 16 weeks in patients with moderate to severe atopic dermatitis May 11, 2021
FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis May 3, 2021
RSS